Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Disorderly Brexit May Necessitate Drug Airlifts, Sanofi UK Head Warns

Executive Summary

A badly planned British departure from the EU could make airlifting of drugs into the UK necessary to ensure adequate supplies are maintained, Sanofi’s managing director in the UK said.

You may also be interested in...



No-Deal Brexit 'Very Bad' For Business And Patients

Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.

EMA Chief Says Brexit Has Impaired Ability To Support R&D

The reduction in the European Medicines Agency’s activities since the UK voted to leave the EU nearly three years has impaired the regulator's ability to keep up with scientific and regulatory developments, and it is facing more staff losses as a result of its relocation to the Netherlands. However, the agency says it has managed to safeguard its core activities relating to the evaluation and supervision of medicines, and that the EU regulatory network should be able to adapt to Brexit-related changes without jeopardizing the quality of its work.

Helping To Transform Health Care With Digital Therapeutics

Mikaela Odlander, one of In Vivo’s 2021 Rising Leaders, was appointed director of digital therapeutics at Orexo in November 2019. The newly formed digital therapeutics (DTx) arm of the Swedish pharma and digital health company entered the American health care landscape in 2020 with two new products that address substance abuse and mental health problems. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC125332

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel